Gabriel N. Hortobagyi, MD

Articles

Updates to MONALEESA-2 Data in HR+ MBC

November 10th 2021

Important takeaways from MONALEESA-2 trial updates on overall survival data corresponding with the use of ribociclib plus letrozole, as presented at ESMO 2021.

First-Line Approaches for HR+ Metastatic Breast Cancer

November 10th 2021

Options available as first-line therapy for HR+ metastatic breast cancer and variables that impact which CDK4/6 inhibitor and endocrine partner is selected for a patient.

Dr. Gabriel Hortobagyi on the Impact of MONALEESA-2 Trial in HR+ Breast Cancer

November 9th 2016

Gabriel N. Hortobagyi, MD, professor of Medicine at the University of Texas MD Anderson Cancer Center, discusses the MONALEESA-2 trial, which has shown that the addition of ribociclib to letrozole significantly improved progression-free survival (PFS) in postmenopausal women with hormone receptor (HR)­-positive advanced breast cancer.

Dr. Hortobagyi on MONALEESA-2 Trial Results in HR+ Breast Cancer

October 18th 2016

Gabriel N. Hortobagyi, MD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses findings from the phase III MONALEESA-2 trial, which looked at the addition of the CDK 4/6 inhibitor ribociclib to endocrine therapy in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Dr. Hortobagyi Discusses the BOLERO-2 Everolimus Trial

December 8th 2011

Dr. Gabriel Hortobagyi from the MD Anderson Cancer Center Discusses the BOLERO-2 Trial